Patent Issued for Anti-BAG2 antibody and methods of treating cancer (USPTO 12122822).

A patent has been issued for an anti-BAG2 antibody by Medpacto Inc., which specifically binds to a BAG2 polypeptide involved in cancer treatment. The antibody targets the BAG2 protein, which plays a role in apoptosis, cell proliferation, and neurodegenerative diseases. This patent aims to develop an antibody that can inhibit cancer progression by targeting BAG2, potentially improving treatment outcomes for cancer patients. [Extracted from the article]